Abstract 1662
Background
Chemotherapy-induced peripheral neuropathy (CIPN) is an adverse effect of many commonly used chemotherapeutic agents, especially taxane-based regimen (Paclitaxel, nab-Paclitaxel, Docetaxel). The CIPN reduces patients health-related quality of life for years and often results in dose delay, dose reduction or treatment discontinuation. The prophylactic use of controlled cryotherapy (Hilotherapy®) prevents chemotherapy-induced-peripheral neuropathy (CIPN).
Methods
162 breast cancer patients treated with taxane based therapeutic regimen used prophylactic Hilotherapy® to cool hands and feet during chemotherapy infusion between 10/2016 – 02/2019. Hilotherapy® is a new physical thermotherapy device, equiped with hand and foot cuffs to allow a constant cooling in a localized and targeted manner. Continous cooling of hands and feet was performed 30 minutes before to 60 minutes after completing drug infusion with a temperature of 10-12 °C. CIPN symptoms were evaluated after each treatment cycle using common terminology criteria for adverse events (CTCAE). The sustainability of the impact was assessed by long-term datas (Follow Up patient contact every 3 months).
Results
122 patients have finished their chemotherapy treatments with prophylactic hand-feet cooling using Hilotherapy®, 39 patients are still under therapy. 113 patients (92.6%) developed none or mild symptoms of CIPN (grade 0-1). 8 patients (6,6%) reported grade 2 toxicity, 1 patient grade 3 (0,8%). The symptoms of CIPN were reversible. Four weeks after the last chemotherapy treatment, 5 patients (4,5%) still reported grade 2 toxicity, none of them suffered from grade 3. Another 3 months later, 2 patients (2,2%) reported an intermittent toxicity of grade 2. Long-term Follow Up datas confirm the lasting results.
Conclusions
Prophylactic Hilotherapy® prevented limiting CIPN Symptoms (> grade 1) in 93% of patients. 7% of the patients developed reversible toxicities grade 2/3. 4 months after chemotherapy treatment, all patients were without any limiting symptoms (grade ≤ 1), except two patients (grade 2). No dose modifications or treatment interruptions had been necessary.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Hilotherm GmbH.
Disclosure
T. Schaper: Honoraria (self), Advisory / Consultancy: Paxman; Honoraria (self), Travel / Accommodation / Expenses: Hilotherm; Honoraria (self), Advisory / Consultancy: EAoS; Honoraria (self): Roche. M. Darsow: Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: Genomic Health; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy: Amgen. All other authors have declared no conflicts of interest.
Resources from the same session
2831 - Interleukin-6 as a Predictive Marker for Early Response to Induction Chemotherapy in Acute Myeloblastic Leukaemia
Presenter: Salah Khallaf
Session: Poster Display session 1
Resources:
Abstract
6014 - Impact of FLT3-ITD mutation on post-transplant outcome of adult AML is modified by the concomitant NPM1 mutation and pre-transplant remission status: A report from Taiwan Bone Marrow Transplant Registry (TBMTR)
Presenter: Su-peng Yeh
Session: Poster Display session 1
Resources:
Abstract
2914 - Efficacy endpoints studied in clinical trials for early-onset leukaemia
Presenter: Dylan Said
Session: Poster Display session 1
Resources:
Abstract
4691 - High triglyceride is a major risk factor of DIC and differentiation syndrome in acute promyelocytic leukemia
Presenter: Tomohiro Yamakawa
Session: Poster Display session 1
Resources:
Abstract
4395 - DREAMM 4: A Phase I/II single-arm open-label study to explore safety and clinical activity of belantamab mafodotin (GSK2857916) administered in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM)
Presenter: Suzanne Trudel
Session: Poster Display session 1
Resources:
Abstract
2808 - A Phase 1 Study of HMPL-523, a Selective Oral Anti-Spleen Tyrosine Kinase Inhibitor, in Patients with Relapsed or Refractory Lymphoma
Presenter: Nathan Fowler
Session: Poster Display session 1
Resources:
Abstract
4403 - A Phase 1 Study of HMPL-689, a Selective Oral Phosphoinositide 3-Kinase-Delta Inhibitor, in Patients with Relapsed or Refractory Lymphoma
Presenter: Jonathon Cohen
Session: Poster Display session 1
Resources:
Abstract
3357 - A global patient-driven Facebook study in a very rare sarcoma: Health-related quality of life in Epithelioid Hemangioendothelioma (EHE) patients
Presenter: Marije Weidema
Session: Poster Display session 1
Resources:
Abstract
2475 - Qualitative study of patients’ experiences of living with and beyond a soft tissue sarcoma diagnosis: the impact of sarcoma specialist services
Presenter: Ana Martins
Session: Poster Display session 1
Resources:
Abstract
2640 - Health-related quality of life issues of patients affected by desmoid-type fibromatosis; experiences from two countries
Presenter: Milea Timbergen
Session: Poster Display session 1
Resources:
Abstract